Spots Global Cancer Trial Database for liposomal irinotecan
Every month we try and update this database with for liposomal irinotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma | NCT03837977 | Oncology Neuroendocrine ... | Liposomal Irino... Fluorouracil Folinic Acid Docetaxel | 18 Years - | The Christie NHS Foundation Trust | |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | NCT03764553 | Esophageal Canc... | Liposomal Irino... Carboplatin Capecitabine Oxaliplatin 5-fluorouracil Leucovorin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University | |
| Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | NCT05854498 | Metastatic Colo... | Liposomal irino... TAS102 Bevacizumab | 18 Years - | University of Wisconsin, Madison | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | NCT04233866 | Metastatic Panc... Stage IV Pancre... | Fluorouracil Gemcitabine Gemcitabine Hyd... Leucovorin Leucovorin Calc... Liposomal Irino... Nab-paclitaxel Quality-of-Life... Questionnaire A... | 70 Years - | Eastern Cooperative Oncology Group | |
| Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | NCT05854498 | Metastatic Colo... | Liposomal irino... TAS102 Bevacizumab | 18 Years - | University of Wisconsin, Madison | |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | NCT06434090 | Colorectal Canc... | Liposomal irino... Bevacizumab | 18 Years - | Sun Yat-sen University | |
| Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma | NCT04662112 | Pancreatic Canc... Pancreatic Duct... | NASOX | 19 Years - | Asan Medical Center | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | NCT06210971 | Rectal Cancer | liposomal irino... Capecitabine Radiation threa... | 18 Years - 80 Years | Hebei Medical University Fourth Hospital | |
| Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | NCT03736720 | Locally Advance... Locally Advance... Metastatic Dige... Metastatic Panc... Refractory Dige... Refractory Panc... Unresectable Di... Unresectable Pa... | Fluorouracil Leucovorin Liposomal Irino... Quality-of-Life... | 18 Years - | Roswell Park Cancer Institute | |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | NCT06434090 | Colorectal Canc... | Liposomal irino... Bevacizumab | 18 Years - | Sun Yat-sen University | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | NCT06184698 | Colorectal Canc... | liposomal irino... 5-FU LV Bevacizumab | 18 Years - 80 Years | Hebei Medical University Fourth Hospital | |
| Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | NCT05255666 | Triple Negative... Brain Metastase... | Pembrolizumab Liposomal Irino... | 18 Years - | Washington University School of Medicine | |
| Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | NCT06192680 | Colorectal Canc... | Liposomal irino... Capecitabine Bevacizumab | 18 Years - 80 Years | Harbin Medical University | |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | NCT04233866 | Metastatic Panc... Stage IV Pancre... | Fluorouracil Gemcitabine Gemcitabine Hyd... Leucovorin Leucovorin Calc... Liposomal Irino... Nab-paclitaxel Quality-of-Life... Questionnaire A... | 70 Years - | Eastern Cooperative Oncology Group | |
| Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | NCT06184698 | Colorectal Canc... | liposomal irino... 5-FU LV Bevacizumab | 18 Years - 80 Years | Hebei Medical University Fourth Hospital | |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT03739801 | Locally Advance... Metastatic Gast... Metastatic Unre... Unresectable Ga... Gastric Adenoca... Gastroesophagea... | Liposomal Irino... Quality-of-Life... Questionnaire A... Ramucirumab | 18 Years - | University of Southern California | |
| Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer | NCT03986294 | Metastatic Panc... | S1 + Nal-IRI Nal-IRI+Leucovo... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | NCT00734682 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... | Nanoliposomal C... | 18 Years - | University of California, San Francisco | |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | NCT06023641 | Rhabdomyosarcom... | Vincristine Dactinomycin Cyclophosphamid... Surgical Resect... Proton beam rad... Liposomal irino... Vinorelbine Temozolomide Filgrastim, peg... | - 22 Years | St. Jude Children's Research Hospital | |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | NCT06258642 | Small Cell Lung... | Irinotecan Lipo... Anlotinib | 18 Years - 75 Years | Fudan University | |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | NCT03764553 | Esophageal Canc... | Liposomal Irino... Carboplatin Capecitabine Oxaliplatin 5-fluorouracil Leucovorin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT03739801 | Locally Advance... Metastatic Gast... Metastatic Unre... Unresectable Ga... Gastric Adenoca... Gastroesophagea... | Liposomal Irino... Quality-of-Life... Questionnaire A... Ramucirumab | 18 Years - | University of Southern California |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
